First-in-Human Single and Multiple Dose of GLPG2222

NCT02662452 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: GLPG2222 single dose
DRUG: Placebo single dose
DRUG: GLPG2222 multiple doses
DRUG: Placebo multiple doses

Sponsor

Lakefront Biotherapeutics NV